Overview

Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

Status:
Active, not recruiting

Trial end date:
2022-02-28

Target enrollment:

Participant gender:

Summary

To determine the effectiveness of ACH-0144471 (also known as danicopan and ALXN2040) in improving anemia when given with eculizumab for 24 weeks in participants with PNH. Danicopan dose may be increased within each participant, to a maximum of 200 milligrams (mg) three times daily (TID) based on safety and efficacy at protocol-specified time points.

Phase:

Phase 2

Details

Lead Sponsor:

Achillion Pharmaceuticals
Alexion Pharmaceuticals

Collaborator:

Achillion, a wholly owned subsidiary of Alexion

Treatments:

Eculizumab